Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) insider Neal Flomenberg sold 232,968 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $1.09, for a total transaction of $253,935.12. Following the completion of the sale, the insider now directly owns 3,595,608 shares of the company's stock, valued at approximately $3,919,212.72. This trade represents a 6.08 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Neal Flomenberg also recently made the following trade(s):
- On Monday, March 10th, Neal Flomenberg sold 70,384 shares of Tevogen Bio stock. The stock was sold at an average price of $1.09, for a total transaction of $76,718.56.
- On Thursday, March 6th, Neal Flomenberg sold 88,519 shares of Tevogen Bio stock. The stock was sold at an average price of $1.10, for a total transaction of $97,370.90.
- On Tuesday, March 4th, Neal Flomenberg sold 14,639 shares of Tevogen Bio stock. The stock was sold at an average price of $1.28, for a total transaction of $18,737.92.
Tevogen Bio Price Performance
Shares of NASDAQ:TVGN traded down $0.01 during midday trading on Tuesday, reaching $1.15. 193,853 shares of the company's stock were exchanged, compared to its average volume of 5,068,422. The company's 50 day simple moving average is $1.36 and its two-hundred day simple moving average is $1.18. Tevogen Bio Holdings Inc. has a 12 month low of $0.26 and a 12 month high of $6.25.
Wall Street Analysts Forecast Growth
Separately, D. Boral Capital reaffirmed a "buy" rating and set a $10.00 price objective on shares of Tevogen Bio in a report on Tuesday, March 11th.
Check Out Our Latest Research Report on TVGN
Institutional Investors Weigh In On Tevogen Bio
A number of hedge funds have recently made changes to their positions in TVGN. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Tevogen Bio during the 4th quarter worth about $38,000. JPMorgan Chase & Co. increased its position in shares of Tevogen Bio by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock worth $40,000 after purchasing an additional 16,695 shares in the last quarter. Barclays PLC increased its position in shares of Tevogen Bio by 39.2% during the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock worth $48,000 after purchasing an additional 12,847 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Tevogen Bio during the 4th quarter worth about $55,000. Finally, HGC Investment Management Inc. acquired a new stake in shares of Tevogen Bio during the 3rd quarter worth about $82,000.
About Tevogen Bio
(
Get Free Report)
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Further Reading
Before you consider Tevogen Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tevogen Bio wasn't on the list.
While Tevogen Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
